Literature DB >> 2948959

Inhibition of phospholipase A2 by "lipocortins" and calpactins. An effect of binding to substrate phospholipids.

F F Davidson, E A Dennis, M Powell, J R Glenney.   

Abstract

The "lipocortins" are a group of proteins that have been reported to inhibit phospholipase A2 by direct interaction with enzyme. Two proteins which have been identified as lipocortin on the basis of inhibition of phospholipase A2 activity have recently been cloned and sequenced. These have been shown to be identical to the calpactins, which are membrane cytoskeletal proteins serving as major substrates of the tyrosine protein kinases. We have now found that two forms of calpactin (I and II) inhibit porcine pancreatic phospholipase A2 in an assay using Escherichia coli cells or extracted phospholipid vesicles as substrate, but only when the substrate concentration is very low. Both calpactins, as well as another, 73-kDa inhibitory protein, were found to bind purified phospholipids and E. coli cell membranes directly. Kinetic studies show that the inhibition of phospholipase A2 by calpactin can be overcome by high phospholipid substrate concentrations, whether E. coli cells or isolated phospholipid vesicles are used. For example, in the presence of 5 X 10(-10) M phospholipase A2 and 1 X 10(-7) M calpactin, the inhibition decreases from 100 to 0% as phospholipid in vesicles is raised from 2 to 8 microM. The evidence reported here strongly suggests that in vitro inhibition of phospholipase A2 by lipocortin is due to sequestering of the phospholipid substrate by the inhibitor protein, rather than a direct interaction with the phospholipase. These results raise questions about the physiological significance of the inhibition of phospholipases by calpactins.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2948959

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  116 in total

1.  Autoantibodies to recombinant lipocortin-1 in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  N J Goulding; M R Podgorski; N D Hall; R J Flower; J L Browning; R B Pepinsky; P J Maddison
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

2.  Purification and inhibitory profile of phospholipase A2 inhibitors from Australian elapid sera.

Authors:  P G Hains; K W Broady
Journal:  Biochem J       Date:  2000-02-15       Impact factor: 3.857

3.  Inhaled budesonide regimen enhances serotonin- and arachidonic acid-induced platelet aggregation.

Authors:  L Hasselmark; R Malmgren; A Dumitrescu
Journal:  Agents Actions       Date:  1992-05

Review 4.  Activation and regulation of protein kinase C enzymes.

Authors:  G L Nelsestuen; M D Bazzi
Journal:  J Bioenerg Biomembr       Date:  1991-02       Impact factor: 2.945

Review 5.  Synovial fluid phospholipase A2s and inflammation.

Authors:  H Gonzalez-Buritica; M A Khamashita; G R Hughes
Journal:  Ann Rheum Dis       Date:  1989-04       Impact factor: 19.103

Review 6.  Mammary gland involution as a multi-step process.

Authors:  Torsten Stein; Nathan Salomonis; Barry A Gusterson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2007-03       Impact factor: 2.673

7.  Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase/PGE isomerase.

Authors:  M Goppelt-Struebe; D Wolter; K Resch
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

8.  Effect of topical steroid (0.05% clobetasol propionate) treatment in children with severe phimosis.

Authors:  Chan Ho Lee; Sang Don Lee
Journal:  Korean J Urol       Date:  2013-09-10

9.  Antiinflammatory action of thielocin A1 beta, a group II phospholipase A2 specific inhibitor, in rat carrageenan-induced pleurisy.

Authors:  K Tanaka; T Kato; K Matsumoto; T Yoshida
Journal:  Inflammation       Date:  1993-04       Impact factor: 4.092

10.  Functional implications of nitric oxide produced by mitochondria in mitochondrial metabolism.

Authors:  C Giulivi
Journal:  Biochem J       Date:  1998-06-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.